Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro

References

• Cleary P. E., Ryan S. J. Mechanisms in traction retinal detachment. Dev. Ophthalmol. 1981; 2: 328–333
   PubMedGoogle Scholar
• Freeman H. M. Recent advances in vitreous surgery. Invest. Ophthalmol. Vis. Sci. 1973; 12: 549–551
   Google Scholar
• Machemer R. Massive periretinal proliferation: a logical approach to therapy. Trans. Am. Ophthalmol. Soc. 1977; 75: 556–586
   PubMedGoogle Scholar
• Shafer D. M. Total vitrectomy for massive retinal contracture. Retina Congress, R. C. Pruett, C. D. Regan. Appleton-Century-Crofts, New York 1974; 703
   Google Scholar
• Hilton G., Machemer R., Okun E., Schepens C., Schwarz A. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121–125
   PubMed Web of Science ®Google Scholar
• Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br. J. Ophthalmol. 1978; 62: 737–747
   PubMed Web of Science ®Google Scholar
• Kampik A., Kenyon K. R., Michels R. G., Green W. R., de la Cruz Z. C. Epiretinal and vitreous membranes: comparative study of 56 cases. Arch. Ophthalmol. 1981; 99: 445–454
   Google Scholar
• Wiedemann P., Heimann K. Proliferative vitre-oretinopathy-pathogenesis and treatment with antiprolifer-ative drugs. Klin. Mbl. Augenheilk. 1986; 188: 559–562
   PubMed Web of Science ®Google Scholar
• Machemer R., Sugita G., Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc. 1979; 77: 171–180
   PubMedGoogle Scholar
• Blumenkranz M. S., Ophir A., Claflin A. J., Hajek A. Fluorouracil for the treatment of massive peri-retinal proliferation. Am. J. Ophthalmol. 1982; 94: 458–467
   PubMed Web of Science ®Google Scholar
• Wiedemann P., Lemmen K., Schmiedl R., Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am. J. Ophthalmol. 1987; 104: 10–14
   PubMed Web of Science ®Google Scholar
• Wiedemann P., Sorgente N., Bekhor C., Patterson R., Tran T., Ryan S. J. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1985; 26: 719–725
   PubMed Web of Science ®Google Scholar
• Santana M., Wiedemann P., Kirmani M., Minckler D. S., Patterson R., Sorgente N., Ryan R. Daunomycin in the treatment of experimental vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefe's Arch. Clin. Exp. Ophthalmol. 1984; 221: 210–213
   PubMed Web of Science ®Google Scholar
• Maral R. J., Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treatment Reports 1981; 65(Suppl. 4)9–18
   PubMedGoogle Scholar
• Wiedemann P., Kirmani M., Santana M., Sorgente N., Ryan S. J. Control of experimental massive peri-retinal proliferation by daunomycin: dose-response relation. Graefe's Arch. Clin. Exp. Ophthalmol. 1983; 220: 233–235
   PubMed Web of Science ®Google Scholar
• Westendorf J., Marquardt H., Marquardt H. Anthracycline antitumour antibiotics: their carcinogenicity and their mutagenicity. Anthracycline Antibiotics in Cancer Therapy, F. M. Muggia, C. W. Young, S. Carter. Martinus Nijhoff, The Hague 1982; 30–49
   Google Scholar
• Westendorf J., Marquardt H., Marquardt H. Structure-activity relationship of anthracycline-induced genotoxicity. Cancer Res. 1984; 44: 5599–5604
   PubMed Web of Science ®Google Scholar
• Suzuki H., Kawashima K., Yamada K. Acla-cinomycin A, a new anti-leucemic agent. Lancet 1979; 2: 870–871
   PubMed Web of Science ®Google Scholar
• Umezawa K., Sawamura M., Matsushima T., Sugi-mura T. Mutagenicity of aclacinomycin A and daunomycin derivatives. Cancer Res. 1978; 32: 1782–1784
   Google Scholar
• Westendorf J., Marquardt H., Ketkar M. B., Mohr U., Marquardt H. Tumorigenicity in vivo and induction mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests. Cancer Res. 1983; 43: 5248–5251
   PubMed Web of Science ®Google Scholar
• Steinhorst U. H., Chen E. P., Hatchell D. L., Samsa G. P., Saloupis P. T., Westendorf J., Machemer R. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1753–1760
   PubMed Web of Science ®Google Scholar
• Flood M. T., Gouras P., Kjeldbye H. Growth characteristics and ultrastructure of human retinal pigment epithelium. in vitro. Invest. Ophthalmol. Vis. Sci. 1980; 19: 1309–1320
   PubMed Web of Science ®Google Scholar
• Kirmani M., Santana M., Sorgente N., Wiedemann P., Ryan S. J. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 1983; 3: 269–272
   PubMed Web of Science ®Google Scholar
• Kirmani M., Santana M., Sorgente N., Wiedemann P., Ryan S. J. Drug treatment of MPP. (Abstract). Invest. Ophthalmol. Vis. Sci. 1983; 24(Suppl.)241
   Google Scholar
• Weller M., Heimann K., Wiedemann P. Cytotoxic effects of daunomycin on retinal pigment epithelium. in vitro. Graefe's Arch. Clin. Exp. Ophthalmol. 1987; 225: 235–238
   PubMed Web of Science ®Google Scholar
• Wiedemann P., Evans P. Y., Wiedemann R., Meyer-Schwickerath R., Heimann K. A fluorescein angiographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin. Int. Ophthalmol. 1989; 13: 211–216
   PubMed Web of Science ®Google Scholar
• Acton E. M. N-alkylation of anthracyclines. Anthracyclines: Current Status and New Developments, S. T. Crooke, S. D. Reich. Academic, New York 1980; 15–25
   Google Scholar
• Zenebergh A., Baurain R., Trouet A. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Cancer Chemother. Pharmacol. 1982; 8: 243–249
   PubMed Web of Science ®Google Scholar
• Bachur N. R., Steele M., Meriwether W. D., Hilde-brandt R. C. Cellular pharmacodynamics of several anthracycline antibiotics. J. Med. Chem. 1976; 19: 651
   PubMed Web of Science ®Google Scholar
• Wheeler C. S., Kessel D. Influx of anthracyclines by murine leucemia cells as a function of drug lipophi-licity and membrane fluidity. Pharmacologist 1980; 22: 291
   Google Scholar
• Tone H., Nishida H., Takeuchi T., Umezawa H. Experimental studies on aclacinomycin. Drugs Exp. Clin. Res. 1985; 11: 9–15
   PubMedGoogle Scholar
• Yamaki H., Suzuki H., Nishimura T., Tanaka M. Mechanism of action of aclacinomycin A1: the effect on macromolecular synthesis. J. Antibiot. 1978; 31: 1149
   PubMed Web of Science ®Google Scholar